Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Enekinragene Inzadenovec · FX-201, GQ-203

Gene therapy · Antagonist of interleukin-1 receptor (IL1R1) · developed by Pacira Pharmaceuticals

Phase 2 Most advanced trial
PCRX Developer
2 Registered trials

What is Enekinragene Inzadenovec?

Enekinragene Inzadenovec is a gene therapy that delivers an interleukin-1 receptor antagonist (IL-1Ra) gene, administered by intra-articular injection. It is being studied for the treatment of knee osteoarthritis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
FX-201, GQ-203
Drug type
Gene therapy
Targets
interleukin-1 receptor (IL1R1)
Mechanism
Antagonist of interleukin-1 receptor (IL1R1)
Pathways
IL-1 signaling
Therapy area
Musculoskeletal
Developer
Pacira Pharmaceuticals, Inc (PCRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
3KJ43QLJ8F

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06884865 Phase 2 Osteoarthritis (OA) of the Knee Recruiting PCRX
NCT04119687 Phase 1 Osteoarthritis, Knee Active not recruiting PCRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Osteoarthritis (OA) of the KneeOsteoarthritis, Knee

More from Pacira Pharmaceuticals

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PCRX page.

Follow PCRX, the company behind Enekinragene Inzadenovec

See PCRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PCRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.